Berlin - Delayed Quote EUR

Merck KGaA (MRK.BE)

119.90

+1.45

+(1.22%)

At close: 8:01:38 AM GMT+2

Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks

Germany’s Merck KGaA is finally nearing a roughly $3.5 billion deal for SpringWorks Therapeutics a U.S. biopharmaceutical company that specializes in rare diseases and cancer. The two parties are discussing a deal around $47 per share, Merck said in a statement Thursday, confirming an earlier report in The Wall Street Journal. Merck said no final agreement had been made.

The Wall Street Journal 1 hour ago

SWTX

MKGAF

MKKGY
SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Investing.com 3 hours ago

MRK.DE
-0.70%
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments. Merck said that the companies are in discussions on the basis of a price of around $47 per share, which gives a valuation of roughly $3.5 billion, according to Reuters calculations. No final decision has been taken and no legally binding agreement has been entered into, Merck said in a statement.

Reuters 4 hours ago

MRK.DE
-0.70%
Are Investors Undervaluing Merck KGaA (ETR:MRK) By 49%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck KGaA fair value estimate is €239 Merck KGaA's €121 share...

Simply Wall St. 19 hours ago

MKGAF

MKKGY
There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Shareholders appeared unconcerned with Merck KGaA's ( ETR:MRK ) lackluster earnings report last week. We did some...

Simply Wall St. last month

MKGAF

MKKGY
Merck KGaA (ETR:MRK) Has Announced A Dividend Of €2.20

The board of Merck KGaA ( ETR:MRK ) has announced that it will pay a dividend of €2.20 per share on the 30th of April...

Simply Wall St. last month

MKGAF

MKKGY
Merck KGaA Full Year 2024 Earnings: EPS Misses Expectations

Merck KGaA ( ETR:MRK ) Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net income...

Simply Wall St. last month

MKGAF

MKKGY
Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Merck KGaA (MKGAF) reports robust Q4 results with significant growth across sectors, despite challenges in Life Science and Electronics.

GuruFocus.com last month

MRK.DE
-0.70%
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Pharmaceutical Technology last month

MRK.DE
-0.70%
GLDAF
Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years

The simplest way to invest in stocks is to buy exchange traded funds. But in our experience, buying the right stocks...

Simply Wall St. last month

MKGAF

MKKGY
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

The company reported a rise in earnings on temporarily-reduced research and development expenses in its healthcare segment and strict cost discipline.

The Wall Street Journal last month

MKGAF

MKKGY
Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production. The German group said in a statement that 2025 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would likely reach between 6.1 billion euros ($6.6 billion) and 6.6 billion euros. That would be up from 6.07 billion euros reported for 2024, which was broadly in line with the average analyst estimate.

Reuters last month

MRK.DE
-0.70%
New CEOs to join Merck KGaA’s executive board

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Pharmaceutical Technology 2 months ago

MRK.DE
-0.70%
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market capitalization of $4.02 billion, according to data from Benzinga Pro. Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met. Reuters was the first to report the potent

Benzinga 2 months ago

MRK.DE
-0.70%
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

BioPharma Dive 2 months ago

THRD

MRK.DE
-0.70%
BBIO
SpringWorks Stock Jumps More Than 30% on News of Possible Deal

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Investopedia 2 months ago

MRK.DE
-0.70%
Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 2 months ago

MRK.DE
-0.70%
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. SpringWorks declined to comment.

Reuters 2 months ago

MRK.DE
-0.70%
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune 2 months ago

PFE

MRK.DE
-0.70%
Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look at where Merck KGaA (OTC:MKGAF) stands against Morgan Stanley’s other European AI stocks. In August last year, investment bank Morgan Stanley released an investor note highlighting that even though the chaos around […]

Insider Monkey 2 months ago

MRK.DE
-0.70%
MS-PQ

Performance Overview

Return	MRK.BE	DAX P (^GDAXI)
YTD	-13.96%	+10.83%
1-Year	-21.17%	+21.98%
3-Year	-30.57%	+56.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MRK.BE)

Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks

SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 49%?

There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Merck KGaA (ETR:MRK) Has Announced A Dividend Of €2.20

Merck KGaA Full Year 2024 Earnings: EPS Misses Expectations

Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

New CEOs to join Merck KGaA’s executive board

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

SpringWorks Stock Jumps More Than 30% on News of Possible Deal

Sector Update: Health Care Stocks Softer Late Afternoon

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

Performance Overview